Tag Archives: ED

Comic-Con: RoboCop Returns

Sony Pictures gave fans at today’s San Diego Comic-Con their first look at their upcoming RoboCop reboot. Stars Joel Kinnaman, Abbie Cornish, Samuel L. Jackson, Michael Keaton and director Jose Padilha were all on hand to screen some footage from the 2014 release.

The first sequence shown was a TV news set-piece following OmniCorp’s deployment of battle droids and ED-209s during the American occupation of Iran during “Operation Freedom.” The TV reporter embedded with the robot military unit is touting their success at keeping the peace — which we see is the pure intimidation of unarmed citizens — when an explosion rocks the street and the OmniCorp droids turn lethal. This entire TV news segment is hosted by Pat Novak, a firebrand pundit on a Fox News-style network. (Jackson described his character as “Rush Sharpton” in a nod to the outspoken duo of Rush Limbaugh and Al Sharpton.)

Continue reading…

…read more

Source: FULL ARTICLE at IGN Movies

Does The World Want, Much Less Need, A New Erectile Dysfunction Drug?

By John LaMattina, Contributor It’s been almost a year since the biotech company, Vivus, announced that the FDA had approved its erectile dysfunction (ED) drug, avanafil (trade name – Stendra). Avanafil, a PDE5 inhibitor, is the fourth member of this class of compounds to be approved for ED – compounds that include two famous predecessors, Viagra (Pfizer) and Cialis (Lilly). …read more
Source: FULL ARTICLE at Forbes Latest

Pfizer Rises to the Occasion and Changes Big Pharma Forever

By Alex Planes, The Motley Fool

Filed under:

On this day in economic and financial history…

Pfizer‘s Viagra (sildenafil citrate), the little blue pill with the big marketing campaign, was first cleared for sale by the FDA on March 27, 1998, becoming the first drug cleared to treat erectile dysfunction in the United States. Originally developed in 1989 at a Pfizer research facility in historic Sandwich, England to treat hypertension and angina pectoris, the drug soon became man’s second-favorite invention to come out of the town of Sandwich when early clinical trials found that it was a lot better at creating erections than curing angina.

Pfizer took the opportunity to penetrate a virtually untapped market. Sildenafil gained a patent in 1996 as it moved through the latter stages of its erectile-dysfunction clinical trials. The drug became a raging success right out of the gate, thrust into the spotlight by one of the first major publicity campaigns ever mounted for a prescription drug. With public figures such as Bob Dole (fresh off his failed 1996 presidential candidacy — you know that if Bill Clinton had lost, he would have been the political pitchman instead) and sports stars like Pele and Rafael Palmeiro promoting it, Viagra became one of Pfizer’s biggest and most durable successes.

In its first year alone, Viagra brought Pfizer a billion dollars in sales. The drug’s smashing success caused several well-endowed competitors to spring up, including Bayer and GlaxoSmithKline‘s Levitra and Eli Lilly’s Cialis. A decade after its introduction, Viagra was producing monster results for Pfizer, accounting for $1.9 billion in annual sales in 2009. Shortly afterward, the global market for erectile dysfunction surpassed $5 billion in cumulative revenue. It was six years after Viagra’s FDA approval that the Dow Jones Industrial Average added Pfizer to its ranks, an acknowledgment of the drugmaker’s impressive quadrupling of revenue over that short time frame.

Viagra couldn’t maintain its position as the market leader forever: Cialis passed the ED pioneer about 12 years after its FDA approval. However, its influence on the drug industry has been more important than its impact on Pfizer’s bottom line. Sales and marketing have become a much larger part of pharmaceutical companies’ strategies, and roughly 30% of the industry’s expenses are sales- and marketing-related. In some cases, drugmakers spend more on marketing than on research and development! Viagra isn’t set to lose its patent protection until 2019, but with 20 million American men already familiar with it, the drug is likely to remain a blockbuster for years to come.

Polyethylene Pam
Viagra wasn’t the only British chemical with a major March 27 milestone. Research chemists Reginald Gibson and Eric Fawcett, working at Imperial Chemical Industries, accidentally discovered the plastic polyethylene on March 27, 1933. Faulty equipment had introduced unwanted oxygen to a reaction of ethylene and benzaldehyde, creating a lump of plastic substance that held promising opportunities. Within three years, polyethylene …read more
Source: FULL ARTICLE at DailyFinance

5 Offensive and Defensive Funds to Strengthen Your Portfolio

By Dan Caplinger

bull market stocks offensive defensive funds

Filed under: , , , ,

Richard Drew/AP

Investors are getting more excited about the stock market now that it has fully recovered from the financial crisis and started to set new record highs. But if you’re looking to invest now, you have to protect yourself from the possibility that the long bull market could reverse itself.

It’s always tough both financially and psychologically to recover from immediate losses on investments you just bought, so taking steps to avoid big losses is well worth the effort.

With that goal in mind, here are five exchange-traded funds that can strengthen your portfolio against the threat of a possible stockmarket decline while still giving you exposure to further gains if the bull market continues.

iShares MSCI USA Minimum Volatility (USMV)
This ETF seeks out stocks that tend to rise and fall more gently than the overall stock market. With a concentration on health-care stocks like Eli Lilly & Co. (LLY) and consumer-oriented stocks like cereal giant General Mills Inc. (GIS), the iShares ETF focuses on stocks with defensive characteristics that hold up well under any economic environment. That won’t keep the fund from losing money in a falling stock market, but it should help reduce the extent of your losses. And with low costs of just 0.15 percent annually, the ETF doesn’t charge a ton to give you that protection.

PowerShares S&P 500 Low Volatility (SPLV)
Like the iShares ETF above, this fund focuses on low-volatility stocks in defensive industries. But the mix of investments in the PowerShares ETF is different, as it concentrates largely on utility stocks, which make up more than 30 percent of the fund’s portfolio right now. Utility giants Southern Co. (SO) and Consolidated Edison Inc. (ED) provide strong dividend income, and their ability to rely on regulated income from millions of utility customers gives them security even when the economy starts to falter. The fund’s costs of 0.25 percent per year are a bit higher than the iShares ETF but are still reasonable for ETFs generally.

PowerShares S&P 500 BuyWrite (PBP)
At first glance, this ETF looks a lot like a typical index-tracking fund, owning Apple Inc. (AAPL), ExxonMobil Corp. (XOM), and many of the other big companies in the S&P 500. But the twist this ETF uses is to write covered call options against that stock, boosting income at the expense of giving up some of the upside in its stock holdings. During bull markets, that strategy underperforms the overall market, but it produces more favorable results when stocks decline. With expenses of 0.75 percent, the strategy is a bit pricey, but it’s still an interesting way to protect against the full impact of a downturn.

iShares S&P Preferred (PFF)
Stocks come in two flavors: common and preferred. …read more
Source: FULL ARTICLE at DailyFinance

Pall Teams with Saudi Arabia-based Research University to Drive Advances in Filtration Technology

By Business Wirevia The Motley Fool

Filed under:

Pall Teams with Saudi Arabia-based Research University to Drive Advances in Filtration Technology

Collaboration with KAUST to Focus on Evolving Filtration Needs of Industries and Utilities in the Middle East and Globally

PORT WASHINGTON, N.Y.–(BUSINESS WIRE)– Pall Corporation (NYSE: PLL), a global leader in filtration, separation and purification technologies, announced today that it has teamed with the King Abdullah University of Science and Technology (KAUST) in Saudi Arabia to drive advances in water treatment, alternative fuels, and other areas of critical importance to communities and businesses in the Middle East and around the globe. As part of the KAUST Industry Collaboration Program (KICP), Pall will participate in research relating to filtration, separations, and purification technologies.

KICP is a membership-based program aimed at fostering strong and productive partnerships with industry. As an integral component of KAUST Economic Development (ED), KICP maximizes the effectiveness of industrial collaboration within the Kingdom of Saudi Arabia and internationally by engaging key partners. KICP supports ED‘s goal of translating knowledge into economic growth and job creation.

“Pall has been a technology leader in filtration and separation for decades,” said Dr. Brian Muellers, senior vice president of Industrial R&D at Pall. “By becoming part of this collaboration, we can match our deep technical and commercial knowledge with the research capabilities at KAUST and its partners to help further efforts in high-growth areas that will only become more critical in the coming years.”

Pall expects to collaborate with multiple research centers and other industrial partners in a wide variety of research initiatives. Pall will complement the extensive and well-equipped laboratory facilities at KAUST with applications expertise, separations materials and pilot scale systems to develop well-focused and commercially sustainable solutions to challenging separations problems.

“The Middle East is an important growth market for Pall,” said Ruby Chandy, president, Pall Industrial. “Our sales in the Middle East have more than doubled in the last four years. This collaboration illustrates our continued commitment to meeting the current and evolving needs of the region’s industries and utilities.”

About Pall Corporation

Pall Corporation (NYSE:PLL) is a filtration, separation and purification leader providing solutions to meet the critical fluid management needs of customers across the broad spectrum of life sciences and industry. Pall works with customers to advance health, safety and environmentally responsible technologies. The …read more
Source: FULL ARTICLE at DailyFinance

Consolidated Edison's Strong Dividend History Helps Get It To The Top 10

By DividendChannel.com

Consolidated Edison, Inc. (NYSE: ED) has been named as a Top 10 dividend paying utility stock, according to Dividend Channel, which published its weekly ”DividendRank” report. The report noted that among utilities, ED shares displayed both attractive valuation metrics and strong profitability metrics. For example, the recent ED share price of $56.59 represents a price-to-book ratio of 1.4 and an annual dividend yield of 4.35% ? by comparison, the average utility stock in Dividend Channel‘s coverage universe yields 4.0% and trades at a price-to-book ratio of 1.8. The report also cited the strong quarterly dividend history at Consolidated Edison, Inc., and favorable long-term multi-year growth rates in key fundamental data points. …read more
Source: FULL ARTICLE at Forbes Markets

Can A Volunteer Beat A Paid Professional For A Job?

By Caroline Ceniza-Levine, Contributor One job seeker asked: I’m going for an ED position interview tomorrow. My experience is over 10 years in that capacity, but as a non-paid volunteer on a part time basis. Nonetheless, we had great accomplishments in those organizations, but how do I compete with other applicants who have full-time, paid experience? …read more
Source: FULL ARTICLE at Forbes Latest

'Canary In The Trousers': Why Erectile Dysfunction Can Signal Heart Disease

By Alice G. Walton Erectile dysfunction (ED) may not be men?s favorite subject, but a new study shows why it?s one health concern that probably shouldn?t be swept under the, er, rug. Earlier evidence has shown ED to be linked to heart problems, which is a logical connection, since the heart and penis alike rely on a healthy blood flow. If one area?s plumbing is faulty, it makes sense that the other?s might be, too. But what?s new about the current study is that it teases out the relative risk levels for men experiencing mild, moderate, or severe ED. The study finds that even mild ED can increase one?s risk of a heart problem, and even of death.
Source: FULL ARTICLE at Forbes Health

Observation Units For Heart Failure Could Reduce Unnecessary Hospitalizations

By Larry Husten, Contributor Two new papers published in the Journal of the American College of Cardiology propose that most heart failure (HF) patients who present to the emergency department (ED) don’t need to be hospitalized and can be safely managed in an observation unit. Currently, the vast majority of HF patients who show up in […]
Source: FULL ARTICLE at Forbes Latest